78 related articles for article (PubMed ID: 38630265)
21. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
22. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
23. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
24. Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion.
Ahrens ET; Helfer BM; O'Hanlon CF; Lister DR; Bykowski JL; Messer K; Leach BI; Chen J; Xu H; Daniels GA; Cohen EEW
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37339797
[TBL] [Abstract][Full Text] [Related]
25. Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture.
Zenga J; Awan M; Frei A; Foeckler J; Kuehn R; Espinosa OV; Bruening J; Massey B; Wong S; Shreenivas A; Shukla M; Kasprzak J; Sun Y; Shaheduzzaman M; Chen F; Kearl T; Himburg HA
Transl Oncol; 2024 Apr; 42():101899. PubMed ID: 38320395
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea.
Lee M; Jo U; Song JS; Lee YS; Woo CG; Kim DH; Kim JY; Yoon SO; Cho KJ
J Pathol Transl Med; 2023 May; 57(3):166-177. PubMed ID: 37194150
[TBL] [Abstract][Full Text] [Related]
27. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Haring CT; Kana LA; Dermody SM; Brummel C; McHugh JB; Casper KA; Chinn SB; Malloy KM; Mierzwa M; Prince MEP; Rosko AJ; Shah J; Stucken CL; Shuman AG; Brenner JC; Spector ME; Worden FP; Swiecicki PL
Cancer; 2023 Sep; 129(18):2817-2827. PubMed ID: 37162461
[TBL] [Abstract][Full Text] [Related]
28. Adoptive cell transfer immunotherapy for patients with solid epithelial cancers.
Rosenberg SA; Parkhurst MR; Robbins PF
Cancer Cell; 2023 Apr; 41(4):646-648. PubMed ID: 37037613
[TBL] [Abstract][Full Text] [Related]
29. Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges.
Basnayake BWMTJ; Leo P; Rao S; Vasani S; Kenny L; Haass NK; Punyadeera C
Br J Cancer; 2023 May; 128(10):1807-1818. PubMed ID: 36765173
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for head and neck cancer: Present and future.
Fasano M; Corte CMD; Liello RD; Viscardi G; Sparano F; Iacovino ML; Paragliola F; Piccolo A; Napolitano S; Martini G; Morgillo F; Cappabianca S; Ciardiello F
Crit Rev Oncol Hematol; 2022 Jun; 174():103679. PubMed ID: 35395371
[TBL] [Abstract][Full Text] [Related]
32. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Zacharakis N; Huq LM; Seitter SJ; Kim SP; Gartner JJ; Sindiri S; Hill VK; Li YF; Paria BC; Ray S; Gasmi B; Lee CC; Prickett TD; Parkhurst MR; Robbins PF; Langhan MM; Shelton TE; Parikh AY; Levi ST; Hernandez JM; Hoang CD; Sherry RM; Yang JC; Feldman SA; Goff SL; Rosenberg SA
J Clin Oncol; 2022 Jun; 40(16):1741-1754. PubMed ID: 35104158
[TBL] [Abstract][Full Text] [Related]
33. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
[TBL] [Abstract][Full Text] [Related]
34. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
35. Modeling
Knochelmann HM; Rivera-Reyes AM; Wyatt MM; Smith AS; Chamness R; Dwyer CJ; Bobian M; Rangel Rivera GO; Horton JD; Lilly M; Romeo MJ; Timmers CD; Rubinstein MP; Neskey DM; Paulos CM
Oncoimmunology; 2021; 10(1):1959101. PubMed ID: 34408920
[TBL] [Abstract][Full Text] [Related]
36. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC; Wang C; Teer JK; Toloza EM; Yao J; Kim S; Landin AM; Mullinax JE; Saller JJ; Saltos AN; Noyes DR; Montoya LB; Curry W; Pilon-Thomas SA; Chiappori AA; Tanvetyanon T; Kaye FJ; Thompson ZJ; Yoder SJ; Fang B; Koomen JM; Sarnaik AA; Chen DT; Conejo-Garcia JR; Haura EB; Antonia SJ
Nat Med; 2021 Aug; 27(8):1410-1418. PubMed ID: 34385708
[TBL] [Abstract][Full Text] [Related]
37. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
Wang S; Sun J; Chen K; Ma P; Lei Q; Xing S; Cao Z; Sun S; Yu Z; Liu Y; Li N
BMC Med; 2021 Jun; 19(1):140. PubMed ID: 34112147
[TBL] [Abstract][Full Text] [Related]
38. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA; Hamid O; Khushalani NI; Lewis KD; Medina T; Kluger HM; Thomas SS; Domingo-Musibay E; Pavlick AC; Whitman ED; Martin-Algarra S; Corrie P; Curti BD; Oláh J; Lutzky J; Weber JS; Larkin JMG; Shi W; Takamura T; Jagasia M; Qin H; Wu X; Chartier C; Graf Finckenstein F; Fardis M; Kirkwood JM; Chesney JA
J Clin Oncol; 2021 Aug; 39(24):2656-2666. PubMed ID: 33979178
[TBL] [Abstract][Full Text] [Related]
39.
Jiménez-Reinoso A; Nehme-Álvarez D; Domínguez-Alonso C; Álvarez-Vallina L
Front Oncol; 2020; 10():593848. PubMed ID: 33680923
[TBL] [Abstract][Full Text] [Related]
40. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.
Mullinax JE; Hall M; Beatty M; Weber AM; Sannasardo Z; Svrdlin T; Hensel J; Bui M; Richards A; Gonzalez RJ; Cox CA; Kelley L; Mulé JJ; Sarnaik AA; Pilon-Thomas S
J Immunother; 2021 Feb-Mar 01; 44(2):63-70. PubMed ID: 33443972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
